
Alterome Therapeutics: Precision biotech developing targeted therapies for high-value oncogenic drivers.
Alterome Therapeutics, founded with a mission to transform the lives of cancer patients, focuses on precision oncology by developing alteration-specific therapeutics. The company's vision is to accelerate the next wave of targeted therapies through a structure-guided drug discovery approach. This method allows for the precise targeting of high-value, validated oncogenic drivers, addressing areas where patients have limited treatment options. Alterome Therapeutics aims to provide innovative solutions in the biotech sector, particularly for those affected by cancer.
Notable figures associated with Alterome Therapeutics include a team of experts committed to their mission, though specific names are not detailed in the provided information. The company has achieved significant progress in developing targeted therapies, contributing to the broader field of precision medicine. Their impact is evident in their dedication to discovering and designing new treatments that offer hope to cancer patients with few alternatives, positioning them as a vital player in the biotech industry focused on oncology.
Companies similar to Alterome Therapeutics include Nested Therapeutics, Alphina Therapeutics, Synnovation Therapeutics and D2G Oncology.
Alterome Therapeutics was founded in 2021.
Alterome Therapeutics' headquarters is located in San Diego, CA, US.
Alterome Therapeutics' most recent funding round was for $132M (USD) in April 2024.
As of Apr 1, 2024, Alterome Therapeutics has disclosed funding of $231M (USD). Undisclosed round amounts are excluded.
Alterome Therapeutics has 24 employees as of Feb 5, 2024.
D2G Oncology
d2g-oncology.com